Cargando…
Molecular Mechanisms of Inhibitor Development in Hemophilia
The development of neutralizing antibodies in hemophilia is a serious complication of factor replacement therapy. These antibodies, also known as “inhibitors”, significantly increase morbidity within the hemophilia population and lower the quality of life for these patients. People with severe hemop...
Autores principales: | Tieu, Paul, Chan, Anthony, Matino, Davide |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Università Cattolica del Sacro Cuore
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6951349/ https://www.ncbi.nlm.nih.gov/pubmed/31934311 http://dx.doi.org/10.4084/MJHID.2020.001 |
Ejemplares similares
-
Hemophilia A and B: molecular and clinical similarities and differences
por: Castaman, Giancarlo, et al.
Publicado: (2019) -
Co-administration of FVIII with IVIG reduces immune response to FVIII in hemophilia A mice
por: Afraz, Sajjad, et al.
Publicado: (2022) -
Development of inhibitors in hemophilia A: An illustrated review
por: Jardim, Letícia Lemos, et al.
Publicado: (2020) -
PB2647: USE OF EMICIZUMAB FOR THE TREATMENT OF ACQUIRED HEMOPHILIA A: A SYSTEMATIC REVIEW
por: Al-Housni, Zainab, et al.
Publicado: (2023) -
Challenges and successes in the treatment of hemophilia: the story of a patient with severe hemophilia A and high-titer inhibitors
por: Saba, Hussain I, et al.
Publicado: (2011)